Inavolisib
Pharmaceutical standards
- Inavolisib, development code GDC-0077, is an oral targeted therapy drug classified as a PI3K inhibitor, specifically targeting the PI3K-alpha isoform. It is being developed by Genentech or Roche for the treatment of certain cancers. Reference standards of Inavolisib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object
(
[pname] => Inavolisib
[catalogue_number] => PA 09 1710000
[category_ids] => ,81,78,70,82,
[chemical_name] =>
[weight] => 407.38
[form] => C18H19F2N5O4
[cas] => 2060571-02-8
[pslug] => 2060571-02-8-inavolisib-pa091710000
[latest_product] => 0
[linkproducts] => 0
[offers_id] =>
[offers_name] =>
[offers_status] =>
[offers_start_date] =>
[offers_end_date] =>
[pageview] =>
[offers_slug] =>
[offers_product_id] =>
[offers_product_code] =>
[offers_master_id] =>
[offer_percentage] =>
[offers_product_main_cat] =>
)
Catalogue No.:PA 09 1710000
Molecular Formula : C18H19F2N5O4
Molecular Weight : 407.38